Archives: Search / 2019 / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011 / 2010
2019 Archives
Aug 20, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2019 fourth quarter and full year on Tuesday, August 27, 2019, after the market closes.... More |
Aug 1, 2019 Lannett Company, Inc. (NYSE: LCI) today announced the appointment of John Kozlowski as chief financial officer (CFO), effective August 31, 2019. He succeeds Martin Galvan, who, as previously... More |
Jul 8, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into a future exclusive supply and distribution agreement for the approved Levothyroxine Sodium Tablets USP of Cediprof, Inc.,... More |
Jul 3, 2019 Lannett Company, Inc. (NYSE: LCI) today commented on the U.S. Food and Drug Administration's (FDA) denial of a Citizen Petition submitted by Genus Lifesciences requesting that the FDA refuse to... More |
Jun 28, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into a three-year agreement with Elite Pharmaceuticals to be the exclusive U.S. distributor of a Dantrolene Capsules 25 mg, 50... More |
Jun 18, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced marketing Aspirin and Extended-Release Dipyridamole Capsules, 25 mg/200 mg, the therapeutic equivalent to the reference... More |
Jun 12, 2019 Lannett Company, Inc. (NYSE: LCI) today announced its participation at two upcoming investor conferences. Schedule below: Raymond James 2019 Life Sciences and MedTech Conference, at 11:30 a.m. ET,... More |
Jun 5, 2019 Lannett Company, Inc. (NYSE: LCI) today announced the commencement of a human clinical trial of biosimilar insulin glargine, a product the company is co-developing with its strategic alliance... More |
May 29, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced marketing Methylphenidate Hydrochloride Extended Release (ER) tablets USP (CII) in 18 mg, 27 mg, 36 mg and 54 mg strengths,... More |
May 24, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that the company's chief financial officer (CFO), Martin Galvan, 67, will retire on August 30, 2019, following the planned submission of the... More |
May 23, 2019 Lannett Company, Inc. (NYSE: LCI) today announced the appointment of Melissa V. Rewolinski, PhD, to its board of directors, effective July 1, 2019. Following the appointment of Dr. Rewolinski, the... More |
May 21, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that it completed the purchase of approximately $30.5 million, face value, of its Term A Loans in a private transaction. "We are particularly... More |
May 16, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that it has begun marketing a generic version of Adderall®, an immediate-release (IR) mixed salt of a single entity Amphetamine tablet product... More |
- Net Sales, Excluding Levothyroxine, Continues Sequential Quarterly Growth Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2019 third quarter ended March 31, 2019. "Our solid third quarter financial results reflect continued growth of... More |
Apr 30, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that it expects to launch later this quarter Methylphenidate Hydrochloride Extended Release (ER) tablets USP (CII) in 18 mg, 27 mg, 36 mg and 54... More |
Apr 29, 2019 Lannett To Report Fiscal 2019 Third-Quarter Financial Results, Host Conference Call On Monday, May 6 Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2019 third quarter on Monday, May 6, 2019, after the market closes. Lannett management will... More |
Mar 27, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Aspirin and... More |
Mar 21, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that it completed the purchase of approximately $24.2 million principal amount of its Term Loans in open market transactions. The purchases... More |
Mar 11, 2019 --Company Expects to Commence Marketing the Product Near Term-- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Elite Pharmaceuticals and SunGen Pharma to be the exclusive U.S. distributor of a generic version of... More |
Feb 26, 2019 Lannett Company, Inc. (NYSE: LCI) today announced its participation at two upcoming investor conferences. Schedule below: Raymond James 40th Annual Institutional Investors Conference at 1:05 p.m.... More |
Feb 6, 2019 - Recent 17 Product Launches Contributed $40 Million of Net Sales in Fiscal 2019 YTD Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2019 second quarter ended December 31, 2018. "Stellar sales across our product offering drove our strong fiscal... More |
Feb 6, 2019 Product Launches, Cost Savings, Insulin Glargine
|
Jan 30, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2019 second quarter on Wednesday, February 6, 2019, after the market closes. Lannett... More |
Jan 22, 2019 Company Has Begun Marketing Entacapone IR Tablets Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with a strategic alliance partner to be the exclusive U.S. distributor of Trientine Hydrochloride Capsules,... More |